arrow
D

Dean Follmann

national institutes of health
H指数:55
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants

先前感染SARS-CoV-2与未感染的COVAIL试验参与者在二次加强针前后COVID-19风险的T细胞相关性差异

2026-10-060
OAAI
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples

一种免疫相关性研究的测试阴性设计近似于传统的暴露邻近设计,但需要远少量的血液样本。

2025-12-010
PRE
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

针对COVID-19的单克隆抗体暴露前预防的保护阈值模型(SARS-CoV-2变体调整)

2025-10-140
OAAI
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

NVX-CoV2373重组蛋白疫苗PREVENT-19疗效试验中抗体标志物作为严重COVID-19风险免疫相关指标的分析

2025-10-010
PRE
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial

SARS-CoV-2变异株抗体反应的免疫相关性分析:ENSEMBLE疫苗有效性试验

2025-09-290
OAAI
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

与原型加强针mRNA疫苗接种相比,Omicron BA.1基线加强针mRNA疫苗接种对COVAIL试验中COVID-19发病率的影響

Vaccine
IF3.5
2025-09-090
OAAI
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up

验证并利用非SARS-CoV-2呼吸道感染作为一项扩展观察性随访的III期COVID-19疫苗试验中的阴性对照结局。

2025-09-010
PRE
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

在COVE试验的开放标签阶段,年龄和给药间隔对Delta和Omicron新型冠状病毒肺炎发病率的影响

2024-11-250
OA
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
2024-09-261
PRE
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

COVE试验中第三剂mRNA-1273的Omicron新型冠状病毒肺炎免疫相关分析

2024-09-110
OAAI
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
2024-03-112
OAAI
Risk of COVID-19 after natural infection or vaccination

自然感染或接种疫苗后新型冠状病毒肺炎的风险

2023-10-012
OAAI
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
2023-09-297
OAAI
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
2023-06-1718
OAAI
Early Discontinuation of Antibiotics in Patients Admitted With Clinically Suspected Serious Infection but Negative Cultures: Retrospective Cohort Study of Practice Patterns and Outcomes at 111 US Hospitals

临床疑似严重感染但培养阴性的患者早期停用抗生素: 美国111家医院的实践模式和结果的回顾性队列研究

2023-05-231
OA
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
2023-04-1913
OAAI
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial (vol 14, 331, 2023)
2023-03-222
OAAI
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
2023-03-1121
OAAI